Research Collaborations, In-licenses and Acquisitions
Toward Continuous New Drug Discoveries
We are actively pursuing research collaborations with research institutions, including
universities, in Japan and overseas, investing in venture companies with innovative technologies, and making
acquisitions and in-licensing products under development through strategic investments to expand and
strengthen our development pipeline.
Investment and contribution to ventures
We collect information in various ways, including investments in bio-venture funds.
| Investment destination |
Investment fields |
| Apposite Healthcare Fund, L.P. |
Life sciences, healthcare services
Investment in bio-venture fund (PDF/50
KB)
|
| Remiges BioPharma Fund, L.P. |
Pharmaceuticals research and development and other life sciences
Sumitomo
Dainippon Pharma announces Investment in a New Venture Capital Fund (PDF/40 KB)
|
| DEFTA Healthcare Technologies, L.P. |
Leading-edge medical treatments and regenerative medicine, next-generation
medical devices, and healthcare IoT/ICT
Sumitomo Dainippon Pharma Announces Investment in DEFTA Healthcare
Technologies, L.P. (PDF/105 KB)
|
| MPM Oncology Innovations Fund |
Academia and growing early-stage companies that are developing new drug
candidate compounds in the oncology area
Sumitomo Dainippon Pharma Announces Investment in MPM Oncology
Innovations Fund (PDF/139 KB)
|
| Kicker Ventures I, L.P. |
Early-stage companies that seek business opportunities primarily in the U.S.,
Canada, and Japan by harnessing digital healthcare technologies such as digital therapy, smart
devices, data analysis and artificial intelligence (AI), personalized medicine, and cutting-edge
therapeutic devices and pharmaceutical products
Sumitomo Dainippon Pharma
Announces Investment in a Venture Capital Fund (PDF/106 KB)
|
Major Joint Research
Here are some of the major joint research projects we are working on with research
institutions, including universities, in Japan and overseas. We are also promoting new drug discoveries by
implementing “PRISM,” a publicly solicited open innovation activity, to seek original ideas from
universities, research institutions, and companies in Japan and conduct collaborative studies that match our
needs in drug discovery research.
| Joint research partners |
Research contents |
| The Kitasato Institute |
Sumitomo Pharma is conducting joint research with a drug discovery group led by Dr. Satoshi Omura,
Distinguished Emeritus Professor of Kitasato University and the 2015 laureate of the Nobel Prize in
Physiology or Medicine, with the aim of discovering new drugs against infections caused by bacteria with
antimicrobial resistance (AMR). This joint R&D initiative was selected by the Japan Agency for
Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant
program. |
| The Center for iPS Cell Research and Application (CiRA) |
- ①This joint research collaboration between industry and academia,
focusing on a rare intractable disease caused by genetic mutation, aims to use induced pluripotent
stem cells (iPS cells) to identify the pathognomonic mechanism of the disease, identify the most
disease-specific target molecule from various pathological changes of signal transduction, and
screen specific inhibitors against the signal pathway. As a result, the aim is to create an
epoch-making treatment to suppress detrimental conditions in patients.
- ②CiRA and Sumitomo Pharma are conducting joint research and development
to establish the world's first Parkinson's disease treatment using allogeneic iPS cell-derived
dopaminergic neural progenitor cells.
|
| The Center for iPS Cell Research and Application (CiRA) and Hitachi Ltd. |
CiRA, Hitachi Ltd., and Sumitomo Pharma are jointly developing the base technology and evaluation
methods to establish a production process for dopaminergic neural progenitor cells. This will be used to
develop the world's first Parkinson's disease treatment using allogeneic iPS cell-derived dopaminergic
neural progenitor cells. These endeavors are part of the "Project Focused on Developing Key Evaluation
Technology: Evaluation for Industrialization in the Field of Regenerative Medicine" commissioned by The
Japan Agency for Medical Research and Development (AMED). |
| Healios K.K. |
Healios K.K. and Sumitomo Pharma are conducting joint development in Japan of iPS cell-derived retinal
pigment epithelial cells (RPE cells) for the treatment of age-related macular degeneration and other eye
diseases. |
| Keio University and National Hospital Organization Osaka National Hospital |
Under the Research Center Network for Realization of Regenerative Medicine, a joint initiative between
government, industry and academia, Sumitomo Pharma, together with the National Hospital Organization
Osaka National Hospital, is taking part as a contributing organization in the Keio University (Professor
Hideyuki Okano) project on "Regenerative medicine for spinal cord injury and stroke using iPS
cell-derived neural progenitor cells." The goal of the project is to develop a treatment for the
transplantation of iPS cell-derived neural progenitor cells for spinal cord injury. |
| RIKEN |
In basic research, Sumitomo Chemical Co., Ltd. in partnership with RIKEN has succeeded in generating a
three-dimensional retina from human embryonic stem cells, a world first. Following on from this,
Sumitomo Pharma aims to create a treatment available using an allogeneic iPS cell-derived
three-dimensional retina. |
| The Jikei University School of Medicine and Bios |
The two partners and Sumitomo Pharma are working on joint research and development with the goal of
developing renal regenerative medicine using iPS cell-based organogenic niche method, and to achieve its
commercialization by fiscal 2027. |
| Carna Biosciences, Inc. |
Carna Bioscience and Sumitomo Pharma are conducting joint research with a view toward discovering
novel kinase inhibitors indicated for psychiatric and neurological disorders by combining accumulated
Carna Biosciences's know-how on kinase inhibitor discovery with Sumitomo Pharma's know-how on drug
discovery research in the area of neuroscience. |
| Medicines for Malaria Venture (MMV) |
MMV and Sumitomo Pharma are conducting joint research aimed at identifying antimalarial candidate
compounds. The Joint Research has been awarded funding from the Global Health Innovative Technology Fund
(GHIT Fund). |
| Ehime University |
Sumitomo Pharma is conducting joint research and development with Ehime University, etc. on new
malaria vaccines (Malaria disease prevention vaccine, Malaria transmission-blocking vaccine,
Pre-erythrocytic malaria vaccine) |
| NIBIOHN (National Institutes of Biomedical Innovation, Health and Nutrition) |
NIBIOHN and Sumitomo Pharma are conducting joint research for a universal influenza vaccine that
provides broader protection against most influenza. |
Strategic Alliances and Acquisitions
We are actively expanding and strengthening our development pipeline by keeping an eye
on global trends and acquiring products under development through strategic investments. This section
describes the status of products under development at the time of acquisition.
Enzyvant Therapeutics Ltd. (currently, Sumitomo Pharma America, Inc.) (U.S.)
Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant
Sciences (PDF/115KB)
Urovant Sciences Ltd. (currently, Sumitomo Pharma America, Inc.) (U.S.)
Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant
Sciences (PDF/115KB)
Myovant Sciences Ltd. (currently, Sumitomo Pharma America, Inc.) (U.S.)
Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant
Sciences (PDF/115KB)
Altavant Sciences Ltd. (currently, Sumitomo Pharma America, Inc.) (U.S.)
Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant
Sciences (PDF/115 KB)
Tolero Pharmaceutical, Inc. (currently, Sumitomo Pharma America, Inc.) (U.S.)
Sumitomo Dainippon Pharma Completes Acquisition of Tolero Pharmaceuticals, Inc. (US
Biotechnology Company) (PDF/63 KB)
Major in-licensed products
With in-licensing and partnerships, we are considering a wide range of products with
priority given to those in the later stages of development, mainly in the areas of psychiatry and neurology,
oncology, and rare diseases. This section describes the status of planned indications at the time of
in-licensing and partnerships.
JCR Pharmaceuticals Co., Ltd. (Japan)
JCR and Sumitomo Pharma Enter into Co-Promotion Agreement in Japan for IZCARGO® I.V. Infusion
10 mg,a Recombinant Therapeutic for Mucopolysaccharidosis Type II (PDF/160KB)
JCR Pharmaceuticals Co., Ltd. (Japan)
JCR and Sumitomo Dainippon Pharma Enter into Marketing Alliance for Agalsidase Beta BS I.V.
Infusion [JCR], for Treatment of Fabry Disease in Japan (PDF/171KB)
Sinovant Sciences HK Limited (China)
Sumitomo Dainippon Pharma Announces Acquisition of Rights for Certain Sinovant Development
Compounds in China and Other Asian Countries (PDF/135 KB)
Novartis Pharma K.K. (Japan)
Sumitomo Dainippon Pharma Signs a Co-Promotion and Sales Collaboration Agreement for Diabetes
Treatments Equa and EquMet in Japan (PDF/110 KB)
Poxel SA (France)
Sumitomo Dainippon Pharma and Poxel Announce Strategic Partnership for Development and
Commercialization of Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan, China
and Eleven Other Asian Countries (PDF/191 KB)
Torii Pharmaceutical Co. Ltd. (Japan)
Toray Receives Japanese Approval for Additional Indication of Pruritus Treatment REMITCH
CAPSULES 2.5 μg and Promotion to Start (PDF/117 KB)
PTC Therapeutics,Inc.(Acquired from Bio Electron Technology Corporation)(U.S.)
Dainippon Sumitomo Pharma signs a License Agreement with Edison Pharmaceuticals for
therapeutic agents for mitochondria disease (PDF/31 KB)